Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASALTS:0RAM -1.74%75 Intrinsic Value: Projected FCF is kr1.60 as of Jul. 31, 2026, which is 100% below its 10-year median of 13.52. GuruFocus rates LTS:0RAM with a GF Score™ of 75/100 and a GF Value™ of kr25.87 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 632 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 95.41% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-07-31), Vistin Pharma ASA's Intrinsic Value: Projected FCF is kr1.60. The stock price of Vistin Pharma ASA is kr19.75. Therefore, Vistin Pharma ASA's Price-to-Intrinsic-Value-Projected-FCF of today is 12.3.
The historical rank and industry rank for Vistin Pharma ASA's Intrinsic Value: Projected FCF or its related term are showing as below:
LTS:0RAM'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 8.06 Med: 13.52 Max: 16.17
Current: 12.34
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Vistin Pharma ASA was 16.17. The lowest was 8.06. And the median was 13.52.
LTS:0RAM's Price-to-Projected-FCF is ranked worse than 95.41% of 632
companies
in the Drug Manufacturers industry
Industry Median: 1.525
vs LTS:0RAM: 12.34
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Vistin Pharma ASA's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
19.75
/
1.5909647008072
=
12.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistin Pharma ASA Intrinsic Value: Projected FCF Related Terms
Vistin Pharma ASA Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of kr1.60 mean?
Vistin Pharma ASA (LTS:0RAM) has a Intrinsic Value: Projected FCF of kr1.60 as of Jul. 31, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Vistin Pharma ASA and its competitors. This is 88% below median its historical median of 13.52. Over the past decade, Vistin Pharma ASA's Intrinsic Value: Projected FCF has ranged from 8.06 to 16.17. According to the industry distribution chart, Vistin Pharma ASA ranks #603 out of 632 companies in the Drug Manufacturers industry, placing it in the top 95.4%.
Is Vistin Pharma ASA's Intrinsic Value: Projected FCF too high?
Vistin Pharma ASA's current Intrinsic Value: Projected FCF of kr1.60 is 88% below median its 10-year median of 13.52. Over the past 10 years, this metric has ranged from a low of 8.06 to a high of 16.17. Based on the distribution chart, Vistin Pharma ASA ranks #603 out of 632 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Intrinsic Value: Projected FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #603 out of 632 companies for Intrinsic Value: Projected FCF. This places Vistin Pharma ASA in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.53. Historically, Vistin Pharma ASA's own Intrinsic Value: Projected FCF has ranged from 8.06 to 16.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.53, based on 632 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Intrinsic Value: Projected FCF is kr1.60, which is 88% below median its own 10-year median of 13.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.87, compared to a current price of kr19.75 — trading 23.7% below its estimated fair value. The current Intrinsic Value: Projected FCF is kr1.60, which is 88% below median its 10-year median of 13.52. Vistin Pharma ASA's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Intrinsic Value: Projected FCF is kr1.60 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr19.75 is trading 23.7% below its estimated GF Value™ of kr25.87.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Intrinsic Value: Projected FCF: kr1.60 (88% below median its 10-year median of 13.52)
GF Value™: kr25.87 vs. price of kr19.75 (23.7% below fair value)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
75GF Score
Get the complete analysis for LTS:0RAM
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
